MDGL Stock Price | Madrigal Pharmaceuticals Inc P/E, Revenue, EPS, & Forecasts

Madrigal Pharmaceuticals Inc • MDGL

MDGL current price

$311.67+31.65%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

+5.32%

-9.83%

+45.71%

+9.11%

+31.65%

MAX

+229.81%

About Madrigal Pharmaceuticals Inc

Ticker

MDGL

Trading on

NASDAQ

ISIN

US5588681057

Industry

Biotechnology

Sector

Healthcare

CEO

William J. Sibold

Headquarters

Four Tower Bridge, West Conshohocken, PA, United States, 19428

Employees

376

Website

madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Metrics

BasicAdvanced

Market cap

$6.8B

P/E ratio

EPS

-$25.02

Dividend Yield

0.00%

Beta

-0.47

Forward P/E ratio

EBIDTA

$-547M

Ex dividend date

Price & volume

Market cap

$6.8B

Average daily volume

0.3M

90-day return

45.71%

30-day return

-9.83%

7-day return

5.32%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

88.59

Price to book

8.76

Earnings

EPS

-$25.02

EPS estimate (current quarter)

-$6.93

EPS estimate (next quarter)

-$6.08

EBITDA

$-547M

Revenues (TTM)

$76.8M

Revenues per share (TTM)

$3.71

Technicals

Beta

-0.47

52-week High

$368.29

52-week Low

$168.25

50-day moving average

$290.81

200-day moving average

$257.27

Short ratio

6.8

Short %

28.17%

Management effectiveness

ROE (TTM)

129.76%

ROA (TTM)

52.25%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

187.06%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

21.8M

Float

10.7M

Insiders %

8.56%

Institutions %

105.56%

Analyst Insights & forecasts

82% Buy

12% Hold

6% Sell

Based on information from 16 analysts.

Average price target

$373.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$5.68

-$5.28

7.58%

Q4 • 23Beat

-$7.38

-$6.28

17.52%

Q1 • 24Beat

-$7.10

-$7.53

5.71%

Q2 • 24Beat

-$4.92

-$6.91

28.80%

Q3 • 24Beat

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$14.6M

$-152M

1,038.20%

Q2 • 24

$62.2M

$-107M

172.04%

Q3 • 24

324.75%

29.62%

83.43%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$1.1B

$243M

22.07%

Q2 • 24

$1.07B

$296M

27.59%

Q3 • 24

2.41%

22.02%

25.04%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-135M

$-122M

$134M

$-140M

Q2 • 24

$-67M

$-202M

$7.5M

$-67.8M

Q3 • 24

50.36%

65.76%

94.44%

51.62%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Madrigal Pharmaceuticals Inc share?

Madrigal Pharmaceuticals Inc shares are currently traded for $311.67 per share.

How many shares does Madrigal Pharmaceuticals Inc have?

Madrigal Pharmaceuticals Inc currently has 21.8M shares.

Does Madrigal Pharmaceuticals Inc pay dividends?

No, Madrigal Pharmaceuticals Inc doesn't pay dividends.

What is Madrigal Pharmaceuticals Inc 52 week high?

Madrigal Pharmaceuticals Inc 52 week high is $368.29.

What is Madrigal Pharmaceuticals Inc 52 week low?

Madrigal Pharmaceuticals Inc 52 week low is $168.25.

What is the 200-day moving average of Madrigal Pharmaceuticals Inc?

Madrigal Pharmaceuticals Inc 200-day moving average is $257.27.

Who is Madrigal Pharmaceuticals Inc CEO?

The CEO of Madrigal Pharmaceuticals Inc is William J. Sibold.

How many employees Madrigal Pharmaceuticals Inc has?

Madrigal Pharmaceuticals Inc has 376 employees.

What is the market cap of Madrigal Pharmaceuticals Inc?

The market cap of Madrigal Pharmaceuticals Inc is $6.8B.

What is the P/E of Madrigal Pharmaceuticals Inc?

The current P/E of Madrigal Pharmaceuticals Inc is null.

What is the EPS of Madrigal Pharmaceuticals Inc?

The EPS of Madrigal Pharmaceuticals Inc is -$25.02.

What is the PEG Ratio of Madrigal Pharmaceuticals Inc?

The PEG Ration of Madrigal Pharmaceuticals Inc is 0.

What do analysts say about Madrigal Pharmaceuticals Inc?

According to the analysts Madrigal Pharmaceuticals Inc is considered a buy.

Madrigal Pharmaceuticals Inc news

thumb_down_alt

•Negative

Top 3 Health Care Stocks That May Dip This Month

As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga•25 Nov 2024, 13:29

thumb_up_alt

•Positive

3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (MDGL 5.53%). Earlier this year, the up-and-coming biotech received approval of a pioneering liver-disease treatment.

The Motley Fool•23 Nov 2024, 12:46

thumb_up_alt

•Positive

Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?

Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Zacks Investment Research•22 Nov 2024, 15:56